Sonoma Pharmaceuticals Names Marc Umscheid Chief Operating Officer
May 08 2018 - 7:00AM
Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a specialty
pharmaceutical company that develops and markets unique and
effective dermatological solutions, announced today that Marc
Umscheid has been promoted to chief operating officer effective
immediately.
“Since joining Sonoma in January of last year after a 17-year
career at the Clorox Company, Marc has added significant value to
our strategic thinking, brand-building, innovation and digital
marketing efforts,” says Jim Schutz, CEO. “We look forward to
Marc taking on an expanded role while helping us grow
profitably.”
Umscheid is a graduate of Cornell University, where he received
both a BS in business management/finance and an MBA from the
Johnson Graduate School of Management.
About Sonoma Pharmaceuticals, Inc.Sonoma is a
specialty pharmaceutical company that develops and markets unique
and effective solutions for the treatment of dermatological
conditions and advanced tissue care. The company’s products, sold
throughout the United States and internationally, have improved
outcomes for more than five million patients globally by
reducing infections, itch, pain, scarring and harmful
inflammatory responses. The company's headquarters are in Petaluma,
California, with manufacturing operations in the United States
and Latin America. European marketing and sales are
headquartered in Roermond, Netherlands. More information can be
found at www.sonomapharma.com.
Forward-Looking StatementsExcept for historical
information herein, matters set forth in this press release
are forward-looking within the meaning of the “safe harbor”
provisions of the Private Securities Litigation Reform Act of 1995,
including statements about the commercial and technology progress
and future financial performance of Sonoma Pharmaceuticals,
Inc. and its subsidiaries (the “Company”). These forward-looking
statements are identified by the use of words such as “believe,”
“taking on,” and “grow,” among others. Forward-looking statements
in this press release are subject to certain risks and
uncertainties inherent in the Company’s business that could cause
actual results to vary, including such risks
that regulatory clinical and guideline developments may
change, scientific data may not be sufficient to meet
regulatory standards or receipt of required regulatory clearances
or approvals, clinical results may not be replicated in actual
patient settings, protection offered by the
Company’s patents and patent applications may be challenged,
invalidated or circumvented by its competitors, the available
market for the Company’s products will not be as
large as expected, the Company’s products will not be able to
penetrate one or more targeted markets, revenues will not be
sufficient to fund further development and clinical studies,
as well as uncertainties relative to varying product formulations
and a multitude of diverse regulatory and marketing requirements in
different countries and municipalities, and other risks detailed
from time to time in the Company’s filings with the Securities and
Exchange Commission. The Company disclaims any obligation to update
these forward-looking statements, except as required by law.
Sonoma Pharmaceuticals is a registered trademark of Sonoma
Pharmaceuticals, Inc. All other trademarks and service marks are
the property of their respective owners.
Media and Investor
Contact:
Sonoma Pharmaceuticals,
Inc.
Bob MillerCFO(925) 787-6218
Sonoma Pharmaceuticals (NASDAQ:SNOA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Sonoma Pharmaceuticals (NASDAQ:SNOA)
Historical Stock Chart
From Sep 2023 to Sep 2024